Analyst consensus rating
Palisade Bio Analyst Rating: Strong Buy
PALI is rated Strong Buy by 9 analysts with a $10.22 target. As of 2026-08-30.
Direct answer
Palisade Bio's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.22.
Forecast evidence checked August 30, 2026.
Get free Palisade Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.00
- Average price target
- $10.22
- High price target
- $25.00
- Low price target
- $5.00
- Low target gap
- +150%
- Target upside
- +411.1%
- High target gap
- +1,150%
- Target range width
- 1,000%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Palisade Bio?
Palisade Bio has a verified Strong Buy consensus. The same dataset has an average price target of $10.22.
How far are Palisade Bio's low and high targets from the recorded price?
The low target implies +150%, while the high target implies +1,150%.
How many analysts are included in Palisade Bio's consensus?
The verified consensus includes 9 analysts.
How is Palisade Bio's target upside or downside calculated?
The average target of $10.22 is divided by the recorded price of $2.00, then one is subtracted to produce +411.1%. This does not guarantee a future return.
When was Palisade Bio's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.